DexCom, Inc. (NASDAQ:DXCM) insider Terrance H. Gregg sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total value of $568,600.00. Following the completion of the sale, the insider now owns 484,559 shares in the company, valued at approximately $27,552,024.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of DexCom, Inc. (NASDAQ DXCM) opened at $56.05 on Friday. DexCom, Inc. has a 12 month low of $42.62 and a 12 month high of $86.32. The stock has a market capitalization of $4,870.91, a P/E ratio of -98.33 and a beta of 0.31. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.11. DexCom had a negative return on equity of 20.44% and a negative net margin of 7.21%. research analysts forecast that DexCom, Inc. will post -0.65 earnings per share for the current year.
Several research firms have commented on DXCM. Northland Securities began coverage on DexCom in a research note on Tuesday, September 26th. They issued an “outperform” rating and a $85.00 target price on the stock. Barclays restated an “equal weight” rating and issued a $60.00 target price (down previously from $76.00) on shares of DexCom in a research note on Thursday, September 28th. Oppenheimer cut their target price on DexCom from $92.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, September 28th. Robert W. Baird cut their target price on DexCom from $79.00 to $58.00 and set a “neutral” rating on the stock in a research note on Thursday, September 28th. Finally, Cowen cut their target price on DexCom from $90.00 to $64.00 and set an “outperform” rating on the stock in a research note on Thursday, September 28th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $68.50.
Hedge funds have recently bought and sold shares of the stock. Winslow Capital Management LLC acquired a new position in shares of DexCom during the 2nd quarter worth approximately $117,451,000. State Street Corp increased its holdings in shares of DexCom by 2.5% during the 2nd quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after acquiring an additional 37,581 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of DexCom by 3.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 265,019 shares of the medical device company’s stock worth $12,967,000 after acquiring an additional 8,171 shares during the last quarter. Peregrine Capital Management LLC increased its holdings in shares of DexCom by 24.5% during the 3rd quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock worth $19,348,000 after acquiring an additional 77,868 shares during the last quarter. Finally, Macquarie Group Ltd. increased its holdings in shares of DexCom by 67.2% during the 2nd quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock worth $17,746,000 after acquiring an additional 97,479 shares during the last quarter.
ILLEGAL ACTIVITY NOTICE: “DexCom, Inc. (DXCM) Insider Sells $568,600.00 in Stock” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/01/21/dexcom-inc-dxcm-insider-sells-568600-00-in-stock.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.